Research Site
Bordeaux, 33000, France
NCT Number: NCT04756700
The primary objective of this study is to establish scores of Cognitive impairment (CI) of the 3 DigiCog [Brief Computerized Cognitive Assessment for Multiple Sclerosis (BCCAMS) app] tests [Computerized Speed Cognitive Test (CSCT), Computerized Episodic Visual Memory Test (CEVMT) and the French Learning Test (FLT), a verbal memory test similar to the CVLT], using a tablet application in a sample of healthy participants matched to persons with MS (PwMS).
The secondary objectives of this study are to determine the ability of the DigiCog app to detect cognitive impairment (CI) compared to the classical Brief International Cognitive Assessment for MS (BICAMS) in PwMS; to determine the relationship between depressive symptoms and cognitive performance in Multiple Sclerosis (MS) sample; to determine the relationship between subjective perception of CI and cognitive performance ; to evaluate the reliability of Konectom™ digital outcome assessments (DOAs) in healthy subjects (HS) and PwMS; to evaluate the convergent validity of Konectom™ digital outcome assessments (DOAs) against in-clinic conventional disability outcome assessments in PwMS; to evaluate differences in Konectom™ DOAs [self administered at home and in-clinic] between PwMS and HS; to evaluate the variability of Konectom™ DOAs self-administered at home in free-living environment in HS and PwMS; to compare Konectom™ DOAs between in-clinic supervised administration versus self-assessments in free-living environment in HS and PwMS; to evaluate the clinical meaningfulness of Konectom™ DOAs against Patient-Reported Outcomes (PRO) in PwMS.
Looking for future studies?
Notify Me18 year–64 year
All sexes
Interventional
Not applicable
Bordeaux, 33000, France
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
For PwMS:
For Healthy Participants:
Exclusion criteria
For PwMS:
For Health Participants:
NOTE: Other protocol defined inclusion/ exclusion criteria may apply.
Administered as specified in the treatment arm.
Administered as specified in the treatment arm.
Time frame: Up to Day 28
Number of the correct answers will provide raw score of CSCT from which regression based norms will be calculated.
Time frame: Up to Day 28
Total number of correct answers of the 3 trials will provide raw score of CEVMT from which regression based norms will be calculated.
Time frame: Up to Day 28
Total number of correct answers for the 5 trials will provide raw score of FLT from which regression based norms will be calculated.
Time frame: Up to Day 28
CI will be defined for DigiCog (BCCAMS app) as one or more abnormal test within the MS sample for DigiCog (BCCAMS app) as well as the BICAMS.
The reference will be CI defined as one or more abnormal BICAMS test.
Time frame: Up to Day 28
CI will be defined for DigiCog (BCCAMS app) as one or more abnormal test within the MS sample for DigiCog (BCCAMS app) as well as the BICAMS.
The reference will be CI defined as one or more abnormal BICAMS test.
Time frame: Up to Day 28
CI will be defined for DigiCog (BCCAMS app) as one or more abnormal test within the MS sample for DigiCog (BCCAMS app) as well as the BICAMS.
The reference will be CI defined as one or more abnormal BICAMS test.
Time frame: Up to Day 28
Depressive symptoms will be estimated by BDI FAST (depressive scale) score. The BICAMS is used as the reference for the cognitive performances. The BCCAMS app is evaluated by using DigiCog scores.
Time frame: Up to Day 28
Subjective perception of CI will be estimated by Daily Cog score. The BICAMS is used as the reference for the cognitive performances.
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Difference between PwMS and HS in the scores of CPS test during each testing condition will be evaluated.
Time frame: Up to Day 28
Difference between PwMS and HS in the score of pinching test during each testing condition will be evaluated
Time frame: Up to Day 28
Difference between PwMS and HS in the score of drawing test during each testing condition will be evaluated.
Time frame: Up to Day 28
Difference between PwMS and HS in the score of grip force test during each testing condition will be evaluated.
Time frame: Up to Day 28
Difference between PwMS and HS in the score of 6MWT test during each testing condition will be evaluated.
Time frame: Up to Day 28
Difference between PwMS and HS in the score of UTT test during each testing condition will be evaluated.
Time frame: Up to Day 28
Difference between PwMS and HS in the score of SBT test during each testing condition will be evaluated.
Time frame: Up to Day 28
Difference between PwMS and HS in the score of mobility behavior test during each testing condition will be evaluated.
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Time frame: Up to Day 28
Biogen
Industry
Validation of DigiCog (BCCAMS App) and Konectom™ Tools, for Supporting Digitalized Clinical Assessment of Cognitive and Motor Functions in Patients With Multiple Sclerosis. DigiToms Study
Acronym: DigiToms
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03963375
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
St Louis, Missouri, United States
View Trial DetailsNCT02511028
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Bethesda, Maryland, United States
View Trial DetailsNCT07175792
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Diepenbeek, Belgium
View Trial DetailsNCT07726667
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Gaziantep, Gaz, Turkey (Türkiye)
View Trial Details